Synthesis of single- and double-chain fluorocarbon and hydrocarbon galactosyl amphiphiles and their anti-HIV-1 activity

Citation
B. Faroux-corlay et al., Synthesis of single- and double-chain fluorocarbon and hydrocarbon galactosyl amphiphiles and their anti-HIV-1 activity, CARBOHY RES, 327(3), 2000, pp. 223-260
Citations number
74
Categorie Soggetti
Agricultural Chemistry","Chemistry & Analysis","Organic Chemistry/Polymer Science
Journal title
CARBOHYDRATE RESEARCH
ISSN journal
00086215 → ACNP
Volume
327
Issue
3
Year of publication
2000
Pages
223 - 260
Database
ISI
SICI code
0008-6215(20000724)327:3<223:SOSADF>2.0.ZU;2-L
Abstract
Galactosylceramide (GalCer) is an alternative receptor allowing HIV-1 entry into CD4(-)/GalCer(+) cells. This glycosphingolipid recognizes the V3 loop of HIV gp120, which plays a key role in the fusion of the HIV envelope and cellular membrane. To inhibit HIV uptake and infection, we designed and sy nthesized analogs of GalCer. These amphiphiles and bolaamphiphiles consist of single and double hydrocarbon and/or fluorocarbon chain beta-linked to g alactose and galactosamine. They derive from serine (GalSer), cysteine (Gal Cys), and ethanolamine (GalAE). The anti-HIV activity and cytotoxicity of t hese galactolipids were evaluated in vitro on CEM-SS (a CD4(+) cell line), HT-29, a CD4(-) cell line expressing high levels of GalCer receptor, and/or HT29 genetically modified to express CD4. GalSer and GalAE derivatives, te sted in aqueous medium or as part of liposome preparation, showed moderate anti-HIV-l activities (IC50 in the 20-220 mu M range), whereas none of the GalCys derivatives was found to be active. Moreover, only some of these ant i-HIV active analogs inhibited the binding of [H-3]suramin (a polysulfonyl. compound which displays a high affinity for the V3 loop) to SPC3, a synthe tic peptide which contains the conserved GPGRAF region of the V3 loop. Our results most likely indicate that the neutralization of the virion through masking of this conserved V3 loop region is not the only mechanism involved in the HIV-1 antiviral activity of our GalCer analogs. (C) 2000 Elsevier S cience Ltd. All rights reserved.